Global Amantadine Hydrochloride (CAS 665-66-7) Market Size By Type (Tablets, Oral Solution), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Amantadine Hydrochloride (CAS 665-66-7) Market was valued at USD 153.2 million in 2023 and is projected to reach USD 231.5 million by 2031, growing at a CAGR of 5.3% during the forecast period from 2023 to 2031. Amantadine Hydrochloride, a compound with antiviral and antiparkinsonian properties, is witnessing steady demand driven by its clinical relevance in treating influenza A, Parkinson's disease, and drug-induced extrapyramidal symptoms. The expansion of the elderly population, growing incidence of neurological disorders, and the increasing repurposing of older drugs for newer therapeutic applications are key factors driving the market.

Drivers:

1. Rising Prevalence of Parkinson’s Disease:

The increasing global geriatric population, which is more susceptible to neurodegenerative disorders like Parkinson’s disease, is significantly boosting demand for amantadine hydrochloride as part of long-term treatment regimens.

2. Clinical Utility Beyond Original Indications:

In addition to its original approval as an antiviral agent, amantadine hydrochloride is being increasingly prescribed off-label for managing multiple sclerosis fatigue and traumatic brain injury symptoms, expanding its therapeutic use cases.

3. Growing Demand for Generic Pharmaceuticals:

With healthcare cost containment policies being enforced globally, there is a growing preference for cost-effective generic alternatives. Amantadine hydrochloride, available in generic formulations, is benefitting from this trend.

Restraints:

1. Adverse Side Effects and Drug Interactions:

Despite its therapeutic benefits, amantadine hydrochloride is associated with central nervous system side effects such as dizziness, hallucinations, and confusion, particularly in elderly patients, limiting its widespread use.

2. Availability of Alternative Therapies:

The increasing availability of advanced antivirals and dopamine agonists with better safety profiles could restrict market growth for amantadine hydrochloride.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies with increasing healthcare access and rising awareness of neurological diseases present untapped opportunities for market expansion.

2. Drug Repurposing and R&D Investments:

Ongoing clinical trials evaluating amantadine for novel indications such as COVID-19 treatment and neuroprotection in traumatic brain injuries are opening new avenues for growth.

Market by System Type Insights:

Based on formulation type, the capsule segment dominated the market in 2023, favored due to ease of administration and established manufacturing processes. However, oral solution formulations are gaining momentum, especially for geriatric and pediatric use, and are projected to witness the highest CAGR through 2031.

Market by End-use Insights:

By end-use, hospitals accounted for the largest share in 2023, driven by rising inpatient admissions for neurological and infectious disease treatment. Retail pharmacies are also witnessing rapid growth due to the increasing availability of generic amantadine hydrochloride over the counter in several regions.

Market by Regional Insights:

North America led the global market in 2023 due to high awareness, advanced healthcare infrastructure, and favorable reimbursement policies. However, Asia-Pacific is projected to grow at the fastest rate owing to rising geriatric population, growing healthcare investments, and increasing generic drug penetration in countries like China and India.

Competitive Scenario:

Key players operating in the Global Amantadine Hydrochloride Market include Zydus Lifesciences, Teva Pharmaceuticals, Glenmark Pharmaceuticals, Mylan N.V., Sun Pharmaceutical Industries Ltd., Sandoz (Novartis AG), Amneal Pharmaceuticals, and Endo International. These companies are focusing on expanding production capabilities, launching generics, and engaging in regulatory approvals to strengthen their market positions.

Scope of Work – Global Amantadine Hydrochloride (CAS 665-66-7) Market

Key Market Developments:

2023: Teva Pharmaceuticals expanded its generic drug portfolio by launching amantadine hydrochloride capsules in Latin America.

2024: Glenmark Pharmaceuticals filed for regulatory approval to market amantadine oral solutions in Southeast Asia.

2025: Zydus Lifesciences began Phase II trials investigating the efficacy of amantadine in treating cognitive dysfunction in long COVID patients.

FAQs:

1) What is the current market size of the Global Amantadine Hydrochloride (CAS 665-66-7) Market?

The market was valued at USD 153.2 million in 2023.

2) What is the major growth driver of the Global Amantadine Hydrochloride (CAS 665-66-7) Market?

The increasing prevalence of Parkinson’s disease and demand for affordable neurotherapeutics are major growth drivers.

3) Which is the largest region during the forecast period in the Global Amantadine Hydrochloride (CAS 665-66-7) Market?

North America holds the largest market share, while Asia-Pacific is the fastest-growing region.

4) Which segment accounted for the largest market share in Global Amantadine Hydrochloride (CAS 665-66-7) Market?

The capsule formulation segment held the largest share in 2023.

5) Who are the key market players in the Global Amantadine Hydrochloride (CAS 665-66-7) Market?

Key players include Zydus Lifesciences, Teva Pharmaceuticals, Glenmark, Mylan, and Sun Pharma.